A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 245 participants.
Also called NCT04959305
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 245 participants
- Registry
-
NCT04959305
-
- Other papers using this trial's data
- Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04959305. Randomized; double masking; primary purpose treatment. Start 2021-04-22 (actual); primary completion 2022-02-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
- Acronym
- HM_APOLLO
- Condition
- Hypertension
- Intervention (Drug)
- HCP1803-3
- Intervention (Drug)
- RLD2003
- Intervention (Drug)
- RLD2004
- Intervention (Drug)
- RLD2005
- Intervention (Drug)
- HPP2003-3
- Intervention (Drug)
- HPP2005
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct04959305- Content hash
636470e181d82655c5ad1f8aa0ae90f6ee4fa1fd46ec56582539d13e2764a6c7